報告摘要

The Global Intravenous (IV) Iron Market is projected to reach USD 9,586.84 million by 2035, expanding at a CAGR of 9.27% during 2025–2035. The market growth is being driven by the rising prevalence of iron deficiency Anaemia and increasing demand for rapid and effective iron replacement therapies. Clinical Superiority of IV Iron in Inflammation-Related Disorders Chronic inflammatory diseases like chronic kidney disease, cancer, and inflammatory bowel disease lead to an increased demand for intravenous (IV) iron therapies. Oral iron may not work well during inflammation as the body's capacity to absorb iron through this route is limited. IV iron, therefore, is considered a more certain and quicker way of addressing Anaemia in these cases. Segment Insights Overview By Product Type • Ferric Carboxymaltose – Widely preferred for rapid high-dose iron replacement. • Ferumoxytol – Gaining demand due to quick administration benefits. • Iron Sucrose – Commonly used in chronic kidney disease treatment. • Iron Isomaltoside – Offers flexible dosing with improved patient tolerance. • Ferric Gluconate – Preferred for controlled and gradual iron supplementation. • Iron Dextran – Suitable for large-dose intravenous iron administration. • Others – Emerging formulations supporting specialized therapeutic requirements. By Application • Anaemia in Chronic Kidney Disease (CKD) – Largest demand driven by dialysis-related Anaemia cases. • Anaemia in Oncology – Increasing use during cancer-related Anaemia management. • Iron Deficiency in Heart Failure – Supporting improved cardiovascular patient health outcomes. • Iron Deficiency Anaemia (IDA) in Non-Dialysis Patients – Rising adoption among outpatient treatment populations. • Others – Expanding applications across diverse chronic medical conditions. By Distribution Channel • Retail Pharmacy – Ensures convenient patient access to prescribed therapies. • Hospital Pharmacy – Dominates distribution through inpatient treatment requirements. • Online Pharmacy – Growing rapidly with digital healthcare adoption trends. By End User • Hospitals and Clinics – Primary centres for intravenous iron administration procedures. • Specialized Infusion Centres – Increasing preference for dedicated infusion-based treatment services. • Others – Includes ambulatory care and alternative healthcare facilities. North America is at the forefront of the Global Intravenous (IV) Iron Market because of its sophisticated healthcare systems and the wide use of IV iron therapies in chronic disease management. On the other hand, Europe, Asia Pacific, South America, and the Middle East & Africa are experiencing increased consumption due to factors like a higher rate of Anaemia and iron deficiency disorders. Strategic Market Expansion In March 2025, Shield Therapeutics partnered with Kye Pharmaceuticals to introduce ACCRUFeR in Canada thereby expanding their international reach. This was an important event because ACCRUFeR is the only prescription-only oral iron therapy that is licensed in Canada. Strategic Edge Through Patient Blood Management Programs As public healthcare systems enhance their capabilities by implementing patient blood management (PBM) programs, the Global Intravenous (IV) Iron Market is benefiting strategically. IV iron treatments can lower the need for blood transfusions as they work well to alleviate Anaemia even before surgeries and in chronic disease scenarios which makes them both cost effective and safer for the patients. Key Report Attributes • Market Size 2035: USD 9,586.84 Million • CAGR (2025-2035): 9.27% • Base Year: 2024 • Market Forecast Period: 2025-2035 Industry Segmentations Growth • By Product Type: Ferric Carboxymaltose - 4,124.87, Ferumoxytol - 1,340.99. • By Application: Anaemia in Chronic Kidney Disease (CKD) - 3,586.84, Anaemia in Oncology - 2,473.47. • By Distribution Channel: Retail Pharmacy - 2,664.00, Hospital Pharmacy - 5,253.75. • By End User: Hospitals and Clinics - 5,649.67, Specialized Infusion Centres - 2,845.49.

目錄 Table of Contents

TABLE OF CONTENTS 1 EXECUTIVE SUMMARY ......... 21 2 MARKET INTRODUCTION ..... 23 2.1 DEFINITION ....... 23 2.2 SCOPE OF THE STUDY ............... 23 2.3 RESEARCH OBJECTIVE ........ 24 2.4 MARKET STRUCTURE ..... 25 3 RESEARCH METHODOLOGY ........... 26 3.1 OVERVIEW ........ 26 3.2 DATA FLOW ......... 27 3.2.1 DATA MINING PROCESS .... 28 3.3 PURCHASED DATABASE: ..... 29 3.4 SECONDARY SOURCES: ....... 30 3.4.1 SECONDARY RESEARCH DATA FLOW: ........ 31 3.5 PRIMARY RESEARCH: ......... 32 3.5.1 PRIMARY RESEARCH DATA FLOW: ............ 33 3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED ........ 34 3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE ......... 34 3.6 APPROACHES FOR MARKET SIZE ESTIMATION: .............. 35 3.6.1 REVENUE ANALYSIS APPROACH .... 35 3.7 DATA FORECASTING ............ 36 3.7.1 DATA FORECASTING TECHNIQUE ............... 36 3.8 DATA MODELING ............... 37 3.8.1 MICROECONOMIC FACTOR ANALYSIS: ....... 37 3.8.2 DATA MODELING: .............. 38 3.9 TEAMS AND ANALYST CONTRIBUTION ............. 39 4 MARKET DYNAMICS ............. 41 4.1 INTRODUCTION ...... 41 4.2 MARKET TRENDS AND GROWTH AFFECTING FACTORS ........ 42 4.3 DRIVERS .............. 42 4.3.1 CLINICAL SUPERIORITY IN INFLAMMATION-DRIVEN IRON DEFICIENCY RISING NEED FOR CONTINUOUS SURVEILLANCE OF SUBMERGED OCEAN AREAS ........... 42 4.3.2 HOSPITAL EFFICIENCY AND RESOURCE OPTIMIZATION ...... 43 4.3.3 GUIDELINE-DRIVEN, PROTOCOLIZED DEMAND ........ 43 4.4 RESTRAINTS ......... 44 4.4.1 HIGH TREATMENT AND ADMINISTRATION COSTS .............. 44 4.4.2 SAFETY MONITORING AND INFRASTRUCTURE REQUIREMENTS ....... 45 4.4.3 UNDERDIAGNOSIS AND INCONSISTENT SCREENING PRACTICES ..... 45 4.5 OPPORTUNITY ....... 47 4.5.1 EXPANSION OF IV IRON USE IN OUTPATIENT AND DAY-CARE SETTINGS ..... 47 4.5.2 RISING FOCUS ON BLOOD MANAGEMENT AND TRANSFUSION REDUCTION ............. 47 4.5.3 UNTAPPED DEMAND IN EMERGING AND UNDERSERVED MARKETS ............. 47 5 MARKET FACTOR ANALYSIS ........... 49 5.1 REGULATORY ENVIRONMENT & COMPLIANCE .... 49 5.2 MARKET TRENDS & INNOVATION ....... 53 5.3 PATIENT DEMOGRAPHICS & DISEASE BURDENS ........... 55 5.3.1 ANEMIA IN CHRONIC KIDNEY DISEASE (CKD) ......... 55 5.3.2 ANEMIA IN ONCOLOGY ...... 55 5.3.3 IRON DEFICIENCY IN HEART FAILURE ......... 55 5.3.4 IRON DEFICIENCY ANEMIA (IDA) IN NON-DIALYSIS PATIENTS ......... 56 5.4 PRICING ANALYSIS & REIMBURSEMENT DYNAMICS ...... 56 5.4.1 PRICING ANALYSIS ............ 56 5.4.1.1 NORTH AMERICA ....... 56 5.4.1.1.1 NORTH AMERICA PRICING ANALYSIS, BY PRODUCT .... 56 5.4.1.2 EUROPE ....... 56 5.4.1.2.1 EUROPE PRICING ANALYSIS, BY PRODUCT ............... 56 5.4.1.3 APAC .......... 57 5.4.1.3.1 APAC PRICING ANALYSIS, BY PRODUCT ..... 57 5.4.1.4 REST OF THE WORLD .............. 57 5.4.1.4.1 REST OF THE WORLD PRICING ANALYSIS, BY PRODUCT ............ 57 5.4.2 REIMBURSEMENT DYNAMICS ........ 57 5.5 MARKET ENTRY & EXIT BARRIERS ........ 58 5.5.1 BARRIERS TO ENTRY ......... 58 5.5.2 BARRIERS TO EXIT ............. 59 5.6 PARTNERSHIPS & COLLABORATIONS .... 60 5.7 PESTLE ANALYSIS ............ 61 5.7.1 POLITICAL FACTORS ......... 61 5.7.2 ECONOMIC FACTORS ........ 61 5.7.3 SOCIAL FACTORS .............. 61 5.7.4 TECHNOLOGICAL FACTORS ........... 62 5.7.5 LEGAL FACTORS ............... 62 5.7.6 ENVIRONMENTAL FACTORS .......... 62 5.8 PORTER’S FIVE FORCES MODEL ......... 63 5.8.1 BARGAINING POWER OF SUPPLIERS .......... 63 5.8.2 BARGAINING POWER OF BUYERS ............... 64 5.8.3 THREAT OF NEW ENTRANTS .......... 64 5.8.4 THREAT OF SUBSTITUTES ............. 64 5.8.5 INTENSITY OF RIVALRY ..... 65 5.9 CASE STUDY ANALYSIS ...... 65 5.10 INVESTMENT & FUNDING SCENARIOS ............. 66 5.11 POST-MARKET SURVEILLANCE & SAFETY DATA .............. 68 5.12 PRODUCT PIPELINE ANALYSIS ..... 69 5.12.1 PRODUCT PIPELINE ANALYSIS ....... 69 6 GLOBAL INTRAVENOUS (IV) IRON MARKET-BY PRODUCT TYPE ........... 71 6.1 INTRODUCTION ...... 71 6.2 FERRIC CARBOXYMALTOSE ............... 73 6.3 FERUMOXYTOL ...... 73 6.4 IRON SUCROSE ...... 73 6.5 IRON ISOMALTOSIDE........... 73 6.6 FERRIC GLUCONATE ............ 74 6.7 IRON DEXTRAN ...... 74 6.8 OTHERS ............... 74 7 GLOBAL INTRAVENOUS (IV) IRON MARKET-BY APPLICATION ............... 75 7.1 INTRODUCTION ...... 75 7.2 ANEMIA IN CHRONIC KIDNEY DISEASE (CKD) ............ 77 7.3 ANEMIA IN ONCOLOGY ....... 77 7.4 IRON DEFICIENCY IN HEART FAILURE ............... 77 7.5 IRON DEFICIENCY ANEMIA (IDA) IN NON-DIALYSIS PATIENTS ..... 77 7.6 OTHERS ............... 78 8 GLOBAL INTRAVENOUS (IV) IRON MARKET-BY DISTRIBUTION CHANNEL ....... 79 8.1 INTRODUCTION ...... 79 8.2 RETAIL PHARMACY ....... 80 8.3 HOSPITAL PHARMACY .............. 80 8.4 ONLINE PHARMACY ...... 81 9 GLOBAL INTRAVENOUS (IV) IRON MARKET-BY END USER ........ 82 9.1 INTRODUCTION ...... 82 9.2 HOSPITAL AND CLINICS ............ 83 9.3 SPECIALISED INFUSION CENTERS .......... 83 9.4 OTHERS ............ 84 10 GLOBAL INTRAVENOUS (IV) IRON MARKET, BY REGION ............ 85 10.1 OVERVIEW ........ 85 10.1.1 GLOBAL INTRAVENOUS (IV) IRON MARKE, BY REGION, 2023 VS 2032 (USD MILLION)........... 85 10.1.2 GLOBAL INTRAVENOUS (IV) IRON MARKET, BY REGION, 2019–2035 (USD MILLION) ............ 86 10.2 NORTH AMERICA ............... 86 10.2.1 US ............ 90 10.2.2 CANADA ............... 92 10.3 EUROPE .............. 94 10.3.1 GERMANY ............. 97 10.3.2 FRANCE .... 99 10.3.3 UK ............ 101 10.3.4 SPAIN ....... 103 10.3.5 ITALY ........ 105 10.3.6 REST OF EUROPE ............... 107 10.4 ASIA-PACIFIC ....... 109 10.4.1 CHINA ....... 113 10.4.2 INDIA ........ 115 10.4.3 JAPAN ...... 117 10.4.4 SOUTH KOREA ....... 119 10.4.5 AUSTRALIA ........... 121 10.4.6 NEW ZEALAND ...... 123 10.4.7 INDONESIA ........... 125 10.4.8 REST OF ASIA-PACIFIC ...... 127 10.5 SOUTH AMERICA ........... 129 10.5.1 BRAZIL ...... 133 10.5.2 MEXICO .... 135 10.5.3 ARGENTINA .......... 137 10.5.4 REST OF SOUTH AMERICA ............. 139 10.6 MIDDLE EAST AND AFRICA ........ 141 10.6.1 GCC COUNTRIES ............... 145 10.6.2 SOUTH AFRICA ...... 147 10.6.3 REST OF MIDDLE EAST & AFRICA ............... 149 11 COMPETITIVE LANDSCAPE ............. 152 11.1 INTRODUCTION ...... 152 11.2 COMPANY MARKET SHARE ANALYSIS, 2024 ............... 152 11.3 COMPETITOR DASHBOARD .... 153 11.4 PUBLIC PLAYERS STOCK SUMMARY ...... 154 11.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL ...... 154 11.6 COMPETITOR'S PRODUCT INFORMATION/ PRODUCT BENCHMARKING ANALYSIS ......... 155 11.7 KEY DEVELOPMENTS & GROWTH STRATEGIES............... 155 11.7.1 NEW PRODUCT LAUNCH/ DEVELOPMENT ......... 155 11.7.2 PARTNERSHIP/COLLABORATION, INVESTMENT, EXPANSION, AND OTHERS ..... 156 12 COMPANY PROFILES ........... 158 12.1 ABBVIE INC. ...... 158 12.1.1 COMPANY OVERVIEW ........ 158 12.1.2 FINANCIAL OVERVIEW ....... 159 12.1.3 PRODUCTS OFFERED ......... 160 12.1.4 KEY DEVELOPMENTS ........ 160 12.1.5 SWOT ANALYSIS ............... 161 12.1.6 KEY STRATEGIES ............... 161 12.2 AZURITY PHARMACEUTICALS .... 162 12.2.1 COMPANY OVERVIEW ........ 162 12.2.2 FINANCIAL OVERVIEW ....... 163 12.2.3 PRODUCTS OFFERED ......... 163 12.2.4 KEY DEVELOPMENTS ........ 164 12.2.5 SWOT ANALYSIS ............... 164 12.2.6 KEY STRATEGIES ............... 165 12.3 DAIICHI SANKYO COMPANY, LTD...... 166 12.3.1 COMPANY OVERVIEW ........ 166 12.3.2 FINANCIAL OVERVIEW ....... 167 12.3.3 PRODUCTS OFFERED ......... 168 12.3.4 KEY DEVELOPMENTS ........ 168 12.3.5 SWOT ANALYSIS ............... 169 12.3.6 KEY STRATEGIES ............... 169 12.4 SANOFI ............... 170 12.4.1 COMPANY OVERVIEW ........ 170 12.4.2 FINANCIAL OVERVIEW ....... 171 12.4.3 PRODUCTS OFFERED ......... 172 12.4.4 KEY DEVELOPMENTS ........ 172 12.4.5 SWOT ANALYSIS ............... 173 12.4.6 KEY STRATEGIES ............... 173 12.5 VIFOR PHARMA (CSL) ........ 174 12.5.1 COMPANY OVERVIEW ........ 174 12.5.2 FINANCIAL OVERVIEW ....... 175 12.5.3 PRODUCTS OFFERED ......... 176 12.5.4 KEY DEVELOPMENTS ........ 177 12.5.5 SWOT ANALYSIS ............... 178 12.5.6 KEY STRATEGIES ............... 178 12.6 PHARMACOSMOS A/S. .............. 179 12.6.1 COMPANY OVERVIEW ........ 179 12.6.2 FINANCIAL OVERVIEW ....... 180 12.6.3 PRODUCTS OFFERED ......... 180 12.6.4 KEY DEVELOPMENTS ........ 180 12.6.5 SWOT ANALYSIS ............... 181 12.6.6 KEY STRATEGIES ............... 181 12.7 ZYDUS GROUP ...... 182 12.7.1 COMPANY OVERVIEW ........ 182 12.7.2 FINANCIAL OVERVIEW ....... 183 12.7.3 PRODUCTS OFFERED ......... 183 12.7.4 KEY DEVELOPMENTS ........ 184 12.7.5 SWOT ANALYSIS ............... 184 12.7.6 KEY STRATEGIES ............... 185 12.8 ROCKWELL MEDICAL, INC. ............... 186 12.8.1 COMPANY OVERVIEW ........ 186 12.8.2 FINANCIAL OVERVIEW ....... 187 12.8.3 PRODUCTS OFFERED ......... 187 12.8.4 KEY DEVELOPMENTS ........ 188 12.8.5 SWOT ANALYSIS ............... 188 12.8.6 KEY STRATEGIES ............... 189 12.9 SHIELD THERAPEUTICS ....... 190 12.9.1 COMPANY OVERVIEW ........ 190 12.9.2 FINANCIAL OVERVIEW ....... 191 12.9.3 PRODUCTS OFFERED ......... 191 12.9.4 KEY DEVELOPMENTS ........ 192 12.9.5 SWOT ANALYSIS ............... 192 12.9.6 KEY STRATEGIES ............... 192 12.10 AMERICAN REGENT, INC ..... 193 12.10.1 COMPANY OVERVIEW ........ 193 12.10.2 FINANCIAL OVERVIEW ....... 194 12.10.3 PRODUCTS OFFERED ......... 194 12.10.4 KEY DEVELOPMENTS ........ 194 12.10.5 SWOT ANALYSIS ............... 195 12.10.6 KEY STRATEGIES ............... 195 12.11 DATA CITATIONS ............... 197

圖表清單 List of Tables & Figures

LIST OF TABLES TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT 39 TABLE 2 GLOBAL INTRAVENOUS (IV) IRON MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 72 TABLE 3 GLOBAL INTRAVENOUS (IV) IRON MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 76 TABLE 4 GLOBAL INTRAVENOUS (IV) IRON MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 80 TABLE 5 GLOBAL INTRAVENOUS (IV) IRON MARKET, BY END USER, 2019-2035 (USD MILLION) 83 TABLE 6 GLOBAL INTRAVENOUS (IV) IRON MARKET, BY REGION, 2019–2032 (USD MILLION) 86 TABLE 7 NORTH AMERICA: INTRAVENOUS (IV) IRON MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 87 TABLE 8 NORTH AMERICA INTRAVENOUS (IV) IRON MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 88 TABLE 9 NORTH AMERICA INTRAVENOUS (IV) IRON MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 88 TABLE 10 NORTH AMERICA INTRAVENOUS (IV) IRON MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 89 TABLE 11 NORTH AMERICA INTRAVENOUS (IV) IRON MARKET, BY END USER, 2019-2035 (USD MILLION) 89 TABLE 12 US INTRAVENOUS (IV) IRON MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 90 TABLE 13 US INTRAVENOUS (IV) IRON MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 90 TABLE 14 US INTRAVENOUS (IV) IRON MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 91 TABLE 15 US INTRAVENOUS (IV) IRON MARKET, BY END USER, 2019-2035 (USD MILLION) 91 TABLE 16 CANADA INTRAVENOUS (IV) IRON MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 92 TABLE 17 CANADA INTRAVENOUS (IV) IRON MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 92 TABLE 18 CANADA INTRAVENOUS (IV) IRON MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 93 TABLE 19 CANADA INTRAVENOUS (IV) IRON MARKET, BY END USER, 2019-2035 (USD MILLION) 93 TABLE 20 EUROPE: INTRAVENOUS (IV) IRON (UUV) MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 95 TABLE 21 EUROPE INTRAVENOUS (IV) IRON MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 95 TABLE 22 EUROPE INTRAVENOUS (IV) IRON MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 96 TABLE 23 EUROPE INTRAVENOUS (IV) IRON MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 96 TABLE 24 EUROPE INTRAVENOUS (IV) IRON MARKET, BY END USER, 2019-2035 (USD MILLION) 96 TABLE 25 GERMANY INTRAVENOUS (IV) IRON MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 97 TABLE 26 GERMANY INTRAVENOUS (IV) IRON MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 97 TABLE 27 GERMANY INTRAVENOUS (IV) IRON MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 98 TABLE 28 GERMANY INTRAVENOUS (IV) IRON MARKET, BY END USER, 2019-2035 (USD MILLION) 98 TABLE 29 FRANCE INTRAVENOUS (IV) IRON MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 99 TABLE 30 FRANCE INTRAVENOUS (IV) IRON MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 99 TABLE 31 FRANCE INTRAVENOUS (IV) IRON MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 100 TABLE 32 FRANCE INTRAVENOUS (IV) IRON MARKET, BY END USER, 2019-2035 (USD MILLION) 100 TABLE 33 UK INTRAVENOUS (IV) IRON MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 101 TABLE 34 UK INTRAVENOUS (IV) IRON MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 101 TABLE 35 UK INTRAVENOUS (IV) IRON MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 102 TABLE 36 UK INTRAVENOUS (IV) IRON MARKET, BY END USER, 2019-2035 (USD MILLION) 102 TABLE 37 SPAIN INTRAVENOUS (IV) IRON MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 103 TABLE 38 SPAIN INTRAVENOUS (IV) IRON MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 103 TABLE 39 SPAIN INTRAVENOUS (IV) IRON MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 104 TABLE 40 SPAIN INTRAVENOUS (IV) IRON MARKET, BY END USER, 2019-2035 (USD MILLION) 104 TABLE 41 ITALY INTRAVENOUS (IV) IRON MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 105 TABLE 42 ITALY INTRAVENOUS (IV) IRON MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 105 TABLE 43 ITALY INTRAVENOUS (IV) IRON MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 106 TABLE 44 ITALY INTRAVENOUS (IV) IRON MARKET, BY END USER, 2019-2035 (USD MILLION) 106 TABLE 45 REST OF EUROPE INTRAVENOUS (IV) IRON MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 107 TABLE 46 REST OF EUROPE INTRAVENOUS (IV) IRON MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 107 TABLE 47 REST OF EUROPE INTRAVENOUS (IV) IRON MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 108 TABLE 48 REST OF EUROPE INTRAVENOUS (IV) IRON MARKET, BY END USER, 2019-2035 (USD MILLION) 108 TABLE 49 ASIA-PACIFIC: INTRAVENOUS (IV) IRON MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 110 TABLE 50 ASIA-PACIFIC INTRAVENOUS (IV) IRON MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 111 TABLE 51 ASIA-PACIFC INTRAVENOUS (IV) IRON MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 111 TABLE 52 ASIA-PACIFIC INTRAVENOUS (IV) IRON MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 112 TABLE 53 ASIA-PACIFIC INTRAVENOUS (IV) IRON MARKET, BY END USER, 2019-2035 (USD MILLION) 112 TABLE 54 CHINA INTRAVENOUS (IV) IRON MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 113 TABLE 55 CHINA INTRAVENOUS (IV) IRON MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 113 TABLE 56 CHINA INTRAVENOUS (IV) IRON MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 114 TABLE 57 CHINA INTRAVENOUS (IV) IRON MARKET, BY END USER, 2019-2035 (USD MILLION) 114 TABLE 58 INDIA INTRAVENOUS (IV) IRON MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 115 TABLE 59 INDIA INTRAVENOUS (IV) IRON MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 115 TABLE 60 INDIA INTRAVENOUS (IV) IRON MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 116 TABLE 61 INDIA INTRAVENOUS (IV) IRON MARKET, BY END USER, 2019-2035 (USD MILLION) 116 TABLE 62 JAPAN INTRAVENOUS (IV) IRON MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 117 TABLE 63 JAPAN INTRAVENOUS (IV) IRON MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 117 TABLE 64 JAPAN INTRAVENOUS (IV) IRON MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 118 TABLE 65 JAPAN INTRAVENOUS (IV) IRON MARKET, BY END USER, 2019-2035 (USD MILLION) 118 TABLE 66 SOUTH KOREA INTRAVENOUS (IV) IRON MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 119 TABLE 67 SOUTH KOREA INTRAVENOUS (IV) IRON MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 119 TABLE 68 SOUTH KOREA INTRAVENOUS (IV) IRON MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 120 TABLE 69 SOUTH KOREA INTRAVENOUS (IV) IRON MARKET, BY END USER, 2019-2035 (USD MILLION) 120 TABLE 70 AUSTRALIA INTRAVENOUS (IV) IRON MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 121 TABLE 71 AUSTRALIA INTRAVENOUS (IV) IRON MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 121 TABLE 72 AUSTRALIA INTRAVENOUS (IV) IRON MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 122 TABLE 73 AUSTRALIA INTRAVENOUS (IV) IRON MARKET, BY END USER, 2019-2035 (USD MILLION) 122 TABLE 74 NEW ZEALAND INTRAVENOUS (IV) IRON MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 123 TABLE 75 NEW ZEALAND INTRAVENOUS (IV) IRON MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 123 TABLE 76 NEW ZEALAND INTRAVENOUS (IV) IRON MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 124 TABLE 77 NEW ZEALAND INTRAVENOUS (IV) IRON MARKET, BY END USER, 2019-2035 (USD MILLION) 124 TABLE 78 INDONESIA INTRAVENOUS (IV) IRON MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 125 TABLE 79 INDONESIA INTRAVENOUS (IV) IRON MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 125 TABLE 80 INDONESIA INTRAVENOUS (IV) IRON MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 126 TABLE 81 INDONESIA INTRAVENOUS (IV) IRON MARKET, BY END USER, 2019-2035 (USD MILLION) 126 TABLE 82 REST OF ASIA-PACIFIC INTRAVENOUS (IV) IRON MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 127 TABLE 83 REST OF ASIA-PACIFIC INTRAVENOUS (IV) IRON MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 127 TABLE 84 REST OF ASIA-PACIFIC INTRAVENOUS (IV) IRON MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 128 TABLE 85 REST OF ASIA-PACIFIC INTRAVENOUS (IV) IRON MARKET, BY END USER, 2019-2035 (USD MILLION) 128 TABLE 86 SOUTH AMERICA: INTRAVENONUS (IV) IRON MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 130 TABLE 87 SOUTH AMERICA: INTRAVENONUS (IV) IRON MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 131 TABLE 88 SOUTH AMERICA: INTRAVENONUS (IV) IRON MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 131 TABLE 89 SOUTH AMERICA: INTRAVENONUS (IV) IRON MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 132 TABLE 90 SOUTH AMERICA: INTRAVENONUS (IV) IRON MARKET, BY END USER, 2019-2035 (USD MILLION) 132 TABLE 91 BRAZI INTRAVENOUS (IV) IRON MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 133 TABLE 92 BRAZIL INTRAVENOUS (IV) IRON MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 133 TABLE 93 BRAZIL INTRAVENOUS (IV) IRON MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 134 TABLE 94 BRAZIL INTRAVENOUS (IV) IRON MARKET, BY END USER, 2019-2035 (USD MILLION) 134 TABLE 95 MEXICO INTRAVENOUS (IV) IRON MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 135 TABLE 96 MEXICO INTRAVENOUS (IV) IRON MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 135 TABLE 97 MEXICO INTRAVENOUS (IV) IRON MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 136 TABLE 98 MEXICO INTRAVENOUS (IV) IRON MARKET, BY END USER, 2019-2035 (USD MILLION) 136 TABLE 99 ARGENTINA INTRAVENOUS (IV) IRON MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 137 TABLE 100 ARGENTINA INTRAVENOUS (IV) IRON MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 137 TABLE 101 ARGENTINA INTRAVENOUS (IV) IRON MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 138 TABLE 102 ARGENTINA INTRAVENOUS (IV) IRON MARKET, BY END USER, 2019-2035 (USD MILLION) 138 TABLE 103 REST OF SOUTH AMERICA INTRAVENOUS (IV) IRON MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 139 TABLE 104 REST OF SOUTH AMERICA INTRAVENOUS (IV) IRON MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 139 TABLE 105 REST OF SOUTH AMERICA INTRAVENOUS (IV) IRON MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 140 TABLE 106 REST OF SOUTH AMERICA INTRAVENOUS (IV) IRON MARKET, BY END USER, 2019-2035 (USD MILLION) 140 TABLE 107 MIDDLE EAST & AFRICA: INTRAVENOUS (IV) IRON, BY COUNTRY, 2019-2035 (USD MILLION) 142 TABLE 108 MIDDLE EAST & AFRICA INTRAVENOUS (IV) IRON MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 143 TABLE 109 MIDDLE EAST & AFRICA INTRAVENOUS (IV) IRON MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 143 TABLE 110 MIDDLE EAST & AFRICA INTRAVENOUS (IV) IRON MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 144 TABLE 111 MIDDLE EAST & AFRICA INTRAVENOUS (IV) IRON MARKET, BY END USER, 2019-2035 (USD MILLION) 144 TABLE 112 GCC COUNTRIES INTRAVENOUS (IV) IRON MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 145 TABLE 113 GCC COUNTRIES INTRAVENOUS (IV) IRON MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 145 TABLE 114 GCC COUNTRIES INTRAVENOUS (IV) IRON MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 146 TABLE 115 GCC COUNTRIES INTRAVENOUS (IV) IRON MARKET, BY END USER, 2019-2035 (USD MILLION) 146 TABLE 116 SOUTH AFRICA INTRAVENOUS (IV) IRON MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 147 TABLE 117 SOUTH AFRICA INTRAVENOUS (IV) IRON MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 147 TABLE 118 SOUTH AFRICA INTRAVENOUS (IV) IRON MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 148 TABLE 119 SOUTH AFRICA INTRAVENOUS (IV) IRON MARKET, BY END USER, 2019-2035 (USD MILLION) 148 TABLE 120 REST OF MIDDLE EAST & AFRICA INTRAVENOUS (IV) IRON MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 149 TABLE 121 REST OF MIDDLE EAST & AFRICA INTRAVENOUS (IV) IRON MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 149 TABLE 122 REST OF MIDDLE EAST & AFRICA INTRAVENOUS (IV) IRON MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 150 TABLE 123 REST OF MIDDLE EAST & AFRICA INTRAVENOUS (IV) IRON MARKET, BY END USER, 2019-2035 (USD MILLION) TABLE 124 PUBLIC PLAYERS STOCK SUMMARY TABLE 125 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL TABLE 126 COMPETITOR'S PRODUCT INFORMATION/ PRODUCT BENCHMARKING ANALYSIS TABLE 127 NEW PRODUCT LAUNCH TABLE 128 PARTNERSHIP/COLLABORATION, INVESTMENT, EXPANSION, AND OTHERS TABLE 129 ABBVIE INC.: PRODUCTS/ SOLUTIONS/ SERVICES OFFERED TABLE 130 ABBVIE INC.: KEY DEVELOPMENTS TABLE 131 AZURITY PHARMACEUTICALS: PRODUCTS/ SOLUTIONS/ SERVICES OFFERED TABLE 132 AZURITY PHARMACEUTICALS: KEY DEVELOPMENTS TABLE 133 DAIICHI SANKYO COMPANY, LTD.: PRODUCTS/ SOLUTIONS/ SERVICES OFFERED TABLE 134 DAIICHI SANKYO COMPANY, LTD.: KEY DEVELOPMENTS TABLE 135 SANOFI: PRODUCTS/ SOLUTIONS/ SERVICES OFFERED TABLE 136 SANOFI: KEY DEVELOPMENTS TABLE 137 VIFOR PHARMA (CSL): PRODUCTS/ SOLUTIONS/ SERVICES OFFERED TABLE 138 VIFOR PHARMA (CSL): KEY DEVELOPMENTS TABLE 139 PHARMACOSMOS A/S.: PRODUCTS/ SOLUTIONS/ SERVICES OFFERED TABLE 140 PHARMACOSMOS A/S.: KEY DEVELOPMENTS TABLE 141 ZYDUS GROUP.: PRODUCTS/ SOLUTIONS/ SERVICES OFFERED TABLE 142 ZYDUS GROUP.: KEY DEVELOPMENTS TABLE 143 ROCKWELL MEDICAL, INC.: PRODUCTS/ SOLUTIONS/ SERVICES OFFERED TABLE 144 ROCKWELL MEDICAL, INC..: KEY DEVELOPMENTS TABLE 145 SHIELD THERAPEUTICS: PRODUCTS/ SOLUTIONS/ SERVICES OFFERED TABLE 146 SHIELD THERAPEUTICS. KG: KEY DEVELOPMENTS TABLE 147 AMERICAN REGENT, INC: PRODUCTS/ SOLUTIONS/ SERVICES OFFERED LIST OF FIGURES FIGURE 1 GLOBAL INTRAVENOUS (IV) IRON MARKET: STRUCTURE FIGURE 2 GLOBAL INTRAVENOUS (IV) IRON MARKET: MARKET GROWTH FACTOR ANALYSIS (2019-2035) FIGURE 3 DRIVER IMPACT ANALYSIS (2019-2035) FIGURE 4 RESTRAINT IMPACT ANALYSIS (2019-2035) FIGURE 5 OPPORTUNITY IMPACT FORECAST FIGURE 6 PORTER’S FIVE FORCES MODEL: GLOBAL INTRAVENOUS (IV) IRON MARKET FIGURE 7 GLOBAL INTRAVENOUS (IV) IRON MARKET, BY PRODUCT TYPE, 2024 & 2035 (USD MILLION) FIGURE 8 GLOBAL INTRAVENOUS (IV) IRON MARKET, BY PRODUCT TYPE, 2024 (% SHARE) FIGURE 9 GLOBAL INTRAVENOUS (IV) IRON MARKET, BY APPLICATION, 2024 & 2035 (USD MILLION) FIGURE 10 GLOBAL INTRAVENOUS (IV) IRON MARKET, BY APPLICATION, 2024 (% SHARE) FIGURE 11 GLOBAL INTRAVENOUS (IV) IRON MARKET, BY DISTRIBUTION CHANNEL, 2024 & 2035 (USD MILLION) FIGURE 12 GLOBAL INTRAVENOUS (IV) IRON MARKET, BY DISTRIBUTION CHANNEL, 2024 (% SHARE) FIGURE 13 GLOBAL INTRAVENOUS (IV) IRON MARKET, BY END USER, 2024 & 2035 (USD MILLION) FIGURE 14 GLOBAL INTRAVENOUS (IV) IRON MARKET, BY END USER, 2024 (% SHARE) FIGURE 15 GLOBAL INTRAVENOUS (IV) IRON MARKET, BY REGION, 2024 (% SHARE) FIGURE 16 GLOBAL INTRAVENOUS (IV) IRON MARKET, BY REGION, 2023 VS 2032 (USD MILLION) FIGURE 17 NORTH AMERICA MARKET ANALYSIS: INTRAVENOUS (IV) IRON MARKET, 2019-2035 (USD MILLION) FIGURE 18 NORTH AMERICA: INTRAVENOUS (IV) IRON MARKET SHARE, BY COUNTRY, 2024 (% SHARE) FIGURE 19 EUROPE MARKET ANALYSIS: INTRAVENOUS (IV) IRON MARKET, 2019-2035 (USD MILLION) FIGURE 20 EUROPE: INTRAVENOUS (IV) IRON MARKET SHARE, BY COUNTRY, 2024 (% SHARE) FIGURE 21 ASIA-PACIFIC MARKET ANALYSIS: INTRAVENOUS (IV) IRON MARKET, 2019-2035 (USD MILLION) FIGURE 22 ASIA-PACIFIC: INTRAVENOUS (IV) IRON MARKET SHARE, BY COUNTRY, 2024 (% SHARE) FIGURE 23 SOUTH AMERICA MARKET ANALYSIS: INTRAVENONUS (IV) IRON MARKET, 2019-2035 (USD MILLION) FIGURE 24 SOUTH AMERICA: INTRAVENONUS (IV) IRON MARKET SHARE, BY COUNTRY, 2024 (% SHARE) FIGURE 25 MIDDLE EAST AND AFRICA MARKET ANALYSIS: INTRAVENOUS (IV) IRON MARKET, 2019-2035 (USD MILLION) FIGURE 26 MIDDLE EAST & AFRICA: INTRAVENOUS (IV) IRON MARKET SHARE, BY COUNTRY, 2024 (% SHARE) FIGURE 27 GLOBAL INTRAVENOUS (IV) IRON PLAYERS: COMPETITIVE ANALYSIS, 2024 (USD BILLION) (% SHARE) FIGURE 28 COMPETITOR DASHBOARD: GLOBAL INTRAVENOUS (IV) IRON MARKET FIGURE 44 SHIELD THERAPEUTICS: SWOT ANALYSIS FIGURE 45 AMERICAN REGENT, INC: SWOT ANALYSIS

Single User Price	$4,950 USD
Multi User Licence (up to 10 users)	$5,950 USD
Enterprisewide Price (Global Site License)	$7,250 USD

授權報價

報告摘要

提及公司

同分類最新報告（醫療與生命科學）